Overview on neoadjuvant trials currently recruiting in melanoma
| Identifier clinicaltrials.gov | Trial name | Compounds |
| NCT03698019 | A Study to Compare the Administration of Pembrolizumab After Surgery vs Administration Both Before and After Surgery for High-Risk Melanoma | Pembrolizumab (anti-PD-1) |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab—PRADO extension cohort | Ipilimumab (anti-CTLA-4) + nivolumab (anti-PD-1) |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients with Clinical Stage III or Oligometastatic Stage IV Melanoma | Nivolumab (anti-PD-1) ± ipilimumab (anti-CTLA-4) or ± relatlimab (anti-LAG-3) |
| NCT02858921 | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma—NeoTrio | Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) ± pembrolizumab (anti-PD-1) |
| NCT03554083 | Neoadjuvant Combination Targeted and Immunotherapy for Patients with High-Risk Stage III Melanoma—NeoACTIVATE | Vemurafenib (BRAF inhibitor) + cobimetinib (MEK inhibitor) ± atezoluzimab (anti-PD-L1) |
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | MGN1703 (TLR-9 agonist)+ipilimumab (anti-CTLA-4) |
| NCT03618641 | Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination with Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease | CMP-001 (TLR-9 agonist) + nivolumab (anti-PD-1) |
| NCT04207086 | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma—Neo PeLe | Lenvatinib (TKI) + anti-PD-1 |
| NCT04133948 | Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-γ Signature-low and IFN-γ Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma—DONIMI | Domatinostat (HDACi) + anti-PD-1 ± anti-CTLA-4 |
BRAF, B-raf proto-oncogene serine/threonine kinase; CTLA-4, cytotoxic T lymphocyte antigen 4; HDACi, histone deacetylase inhibitor; IFN-γ, interferon-gamma; LAG-3, lymphocyte-activation gene 3; MEK, mitogen-activated protein kinase kinase; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; TLR-9, toll-like receptor 9.